How is the Tscan Therapeutics Inc today?

The Tscan Therapeutics Inc today is trading in the down by -3.76% at 1.28.

What is Tscan Therapeutics Inc Annual Revenue?

Tscan Therapeutics Inc Annual Revenue fell 86.62%, in the last year to $2.82 M. Its sector's average revenue growth for the last fiscal year was 8.63%.

What is Tscan Therapeutics Inc Annual Net Profit?

Tscan Therapeutics Inc Annual Net Profit fell 42.91% in the last year to $127.5 M. Its sector's average net profit growth for the last fiscal year was -7.19%.

What is Tscan Therapeutics Inc Price to Earning Ratio?

Tscan Therapeutics Inc Price to Earning Ratio is -0.55, which is negative.

What is Tscan Therapeutics Inc Stock Price?

Tscan Therapeutics Inc Stock Price fell 84.02% and underperformed its sector by 88.49% in the past year.

What is Tscan Therapeutics Inc Quarterly Revenue?

Tscan Therapeutics Inc Quarterly Revenue rose 283.57% YoY to $2.17 M. Its sector's average revenue growth YoY for the quarter was 2.8%.

What is Tscan Therapeutics Inc Quarterly Net profit?

Tscan Therapeutics Inc Quarterly Net profit fell 13.22% YoY to $34.13 M. Its sector's average net profit growth YoY for the quarter was -210.52%.

What is Tscan Therapeutics Inc Debt to Equity Ratio?

Tscan Therapeutics Inc Debt to Equity Ratio of 0.4 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Tscan Therapeutics Inc Return on Equity(ROE)?

Tscan Therapeutics Inc Return on Equity(ROE) for the last financial year was -65.08%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Tscan Therapeutics Inc Mutual Fund Holding?

Tscan Therapeutics Inc Mutual Fund Holding decreased by 0.5% in the last quarter to 20.67.

What is Tscan Therapeutics Inc Interest Coverage Ratio?

Tscan Therapeutics Inc Interest Coverage Ratio is -33.9, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is Tscan Therapeutics Inc Institutional Holding?

Tscan Therapeutics Inc Institutional Holding decreased by 0.05% in the last quarter to 62.03.

Tscan Therapeutics Inc XNAS: TCRX

Tscan Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Name: Tscan Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Tscan Therapeutics Inc
Rating: 0.92733325
Author: Trendlyne DVM scores

about

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and ...

1.28 -0.05 (-3.76%)

86.79% Fall from 52W High

272.4K XNAS Volume

XNAS 14 May, 2025 4:07 PM (EDT)

Not Eligible

-

Expensive Valuation

19.3 / 100

Technically Bearish

17.8 / 100

9

1Yr Price target upside is 603%

7 analysts

Tscan Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Tscan Therapeutics Inc FAQ

How is Tscan Therapeutics Inc today?

Tscan Therapeutics Inc today is trading in the red, and is down by -3.76% at 1.28.

How has Tscan Therapeutics Inc performed historically?

Tscan Therapeutics Inc is currently trading down -3.76% on an intraday basis. In the past week the stock fell -5.88%. stock has been down -37.25% in the past quarter and fell -84.02% in the past year. You can view this in the overview section.